Citadel Advisors’s Beta Bionics BBNX Stock Holding History
Bought
Maintained
Sold
Other funds holding BBNX
Citadel Advisors's BBNX Position: Q3 2026 in Review
Citadel Advisors opened a new position in Beta Bionics (BBNX) in Q3 2026: 103,450 shares worth $1.96M. The stake represents ﹤0.01% of the portfolio and ranks #6746 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in BBNX as recently as Q1 2026.
Citadel Advisors first reported a position in BBNX in Q1 2025 and has held it in 5 quarters since. The position peaked at $11.6M in Q1 2025. 153 funds tracked by Wall St. Rank hold BBNX as of Q3 2026.
- Citadel Advisors held 103,450 shares of Beta Bionics worth $1.96M as of Q3 2026.
- Beta Bionics was a new Citadel Advisors position in Q3 2026.
- Beta Bionics made up ﹤0.01% of Citadel Advisors's portfolio in Q3 2026, its #6746 holding.
- Citadel Advisors first reported a position in Beta Bionics in Q1 2025 and has held it in 5 quarters since.
- Citadel Advisors's Beta Bionics position peaked at $11.6M in Q1 2025.
- 153 funds tracked by Wall St. Rank held Beta Bionics as of Q3 2026.
Based on Citadel Advisors's 13F filing for Q3 2026, filed 16 Nov 2026.